Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Rudolf Weide, Stefan Feiten, Vera Friesenhahn, Jochen Heymanns, Kristina Kleboth, Jörg Thomalla, Christoph van Roye & Hubert Köppler. (2013) Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. Leukemia & Lymphoma 54:8, pages 1640-1646.
Read now
Read now
Fredrick Hagemeister & George Manoukian. (2009) Bendamustine in the treatment of non-Hodgkin’s lymphomas. OncoTargets and Therapy 2, pages 269-279.
Read now
Read now
Ibrahim T Aldoss, Susan M Blumel & Philip J Bierman. (2009) The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma. Cancer Management and Research 1, pages 155-165.
Read now
Read now
Rudolf Weide, Ulrike Mergenthaler, Vera Friesenhahn, Kristina Kleboth, Jochen Heymanns, Jörg Thomalla & Hubert Köppler. (2009) Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 50:9, pages 1468-1474.
Read now
Read now
Rudolf Weide. (2008) Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma. Therapeutics and Clinical Risk Management 4:4, pages 727-732.
Read now
Read now
Rudolf Weide, Georg Hess, Hubert Köppler, Jochen Heymanns, Jörg Thomalla, Ali Aldaoud, Christoph Losem, Stefan Schmitz, Ursula Haak, Christoph Huber, Michael Unterhalt, Wolfgang Hiddemann & Martin Dreyling. (2007) High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leukemia & Lymphoma 48:7, pages 1299-1306.
Read now
Read now
Rudolf Weide, Annette Pandorf, Jochen Heymanns & Hubert Köppler. (2004) Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study. Leukemia & Lymphoma 45:12, pages 2445-2449.
Read now
Read now
Michael Koenigsmann, Wolfgang U Knauf, Michael Herold, Rita Pasold, Gerd Müller, Henning Eschenburg, Christoph Kahl, Volker Lakner, Michael Aßmann, Kathleen Jentsch-Ullrich, Martin Mohren, Rainer Bartsch & Astrid Franke. (2004) Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma—a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO). Leukemia & Lymphoma 45:9, pages 1821-1827.
Read now
Read now
Hubert Köppler, Jochen Heymanns, Annette Pandorf & Rudolf Weide. (2004) Bendamustine Plus Mitoxantrone—A New Effective Treatment for Advanced Chronic Lymphocytic Leukaemia: Results of a Phase I/II Study. Leukemia & Lymphoma 45:5, pages 911-913.
Read now
Read now
Articles from other publishers (14)
Rudolf Weide. (2017) Versorgungsforschung in onkologischen Schwerpunktpraxen in DeutschlandHealth services research in community-based oncology practices in Germany. Der Onkologe 23:11, pages 911-917.
Crossref
Crossref
Liat Vidal, Anat Gafter-Gvili, Ronit Gurion, Pia Raanani, Martin Dreyling & Ofer Shpilberg. (2012) Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Hubert Köppler, Harald Fuss, Hans J. Hurtz, Owe Knigge, Christoph Losem, Daniel Reschke, Stephan Schmitz, Rudolf Weide, Johann Weiß & Michael Hallek. (2012) Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG). British Journal of Haematology 158:2, pages 238-241.
Crossref
Crossref
Liat Vidal, Anat Gafter-Gvili, Ronit Gurion, Pia Raanani, Martin Dreyling & Ofer Shpilberg. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Nishant Tageja. (2011) Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma. Clinical Medicine Insights: Oncology 5, pages CMO.S6085.
Crossref
Crossref
Nishant Tageja & Jasdeepa Nagi. (2010) Bendamustine: something old, something new. Cancer Chemotherapy and Pharmacology 66:3, pages 413-423.
Crossref
Crossref
Dominic A. SolimandoJrJr & J. Aubrey Waddell. (2008) Bendamustine; Levoleucovorin. Hospital Pharmacy 43:8, pages 629-633.
Crossref
Crossref
Andres Forero-Torres & Mansoor N. Saleh. (2007) Bendamustine in Non-Hodgkin Lymphoma: The Double-Agent that Came from the Cold War. Clinical Lymphoma and Myeloma 8, pages S13-S17.
Crossref
Crossref
Barbel Seyfarth, Andreas Josting, Martin Dreyling & Norbert Schmitz. (2006) Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. British Journal of Haematology 133:1, pages 3-18.
Crossref
Crossref
M. Dreyling, C. Buske & W. Hiddemann. (2005) Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma. Annals of Oncology 16, pages ii99-ii104.
Crossref
Crossref
C.-M Wendtner, B.F Eichhorst & M.J Hallek. (2004) Advances in chemotherapy for chronic lymphocytic leukemia. Seminars in Hematology 41:3, pages 224-233.
Crossref
Crossref
Souichi Adachi, Lorenzo M. Leoni, Dennis A. Carson & Tatsutoshi Nakahata. (2004) Apoptosis Induced by Molecular Targeting Therapy in Hematological Malignancies. Acta Haematologica 111:1-2, pages 107-123.
Crossref
Crossref
J. Boye, T. Elter & A. Engert. (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Annals of Oncology 14:4, pages 520-535.
Crossref
Crossref
. (2002) Current Awareness in Hematological Oncology. Hematological Oncology 20:4, pages 189-196.
Crossref
Crossref